Clinical Features and Prognosis of t(8;21) AML Patients in China: A Multicenter Retrospective Study.

Dan Gong; Wei LI; Liang-ding HU; Jian-min Luo; Jian-liang Shen; Mei-yun Fang; Qing-ming Yang; Heng-xiang Wang; Xiao-yan KE; Hui-ren Chen; Zhao Wang; Hui Liu; Feng Liu; Yi-gai MA; Jing-wen Wang; Hong-hua LI; Quan-shun Wang; Yu Jing; Xiao-ning Gao; Li-ping Dou; Yong-hui LI; Li YU

Return

Clinical Features and Prognosis of t(8;21) AML Patients in China: A Multicenter Retrospective Study.

Author: Dan GONG ^{1
,

2} ; Wei LI ³ ; Liang-Ding HU ⁴ ; Jian-Min LUO ⁵ ; Jian-Liang SHEN ⁶ ; Mei-Yun FANG ⁷ ; Qing-Ming YANG ⁸ ; Heng-Xiang WANG ⁹ ; Xiao-Yan KE ¹⁰ ; Hui-Ren CHEN ¹¹ ; Zhao WANG ¹² ; Hui LIU ¹³ ; Feng LIU ¹⁴ ; Yi-Gai MA ¹⁵ ; Jing-Wen WANG ¹⁶ ; Hong-Hua LI ¹⁷ ; Quan-Shun WANG ¹⁷ ; Yu JING ¹⁷ ; Xiao-Ning GAO ¹⁷ ; Li-Ping DOU ¹⁷ ; Yong-Hui LI ¹⁷ ; Li YU ¹⁸
Author Information

1. Department of Hematology, Chinese PLA General Hospital, Beijing 100853,China
2. Department of Hematology, No.222 Hospital of Chinese PLA, Jilin 132011, Jilin Province,China.
3. Department of Hematology, The First Affiliated Hospital of Jilin University, Changchun 130000,Jilin Province, China.
4. Department of Hematology, The Second Affiliated Hospital of Hebei Medical University, Shijia-zhuang 050000, Hebei Province, China.
5. Department of Hematology, No. 307 Hospital of Chinese PLA, Beijing 100071, China.
6. Department of Hematology, Chinese NAVY General Hospital, Beijing 100037, China.
7. Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning Province, China.
8. Department of Diagnosis and Therapy for Carders, The First Affiliated Hospital of Chinese PLA General Hospital, Beijing 100037, China.
9. Department of Hematology, Chinese Air Force General Hospital, Beijing 100142, China.
10. Department of Hematology, Peking University Third Hospital, Beijing 100191, China.
11. Department of Hematology, Chinese PLA Army General Hospital, Beijing 100700, China.
12. Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China.
13. Department of Hematology, Beijing Hospital, Ministry of Health, Beijing 100730, China.
14. Department of Hematology, Xiyuan Hospital of Chinese Academy of Medical Sciences, Beijing 100091, China.
15. Department of Hematology, China-Japan Friendship Hospital, Beijing 100029, China.
16. Department of Hematology, Beijing Tongren Hospital, Beijing 100730, China.
17. Department of Hematology, Chinese PLA General Hospital, Beijing 100853,China.
18. Department of Hematology, Chinese PLA General Hospital, Beijing 100853,China. E-mail:liyu301@163.com.
Publication Type:Journal Article
From: Journal of Experimental Hematology 2017;25(4):980-986
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo summarize the clinical characteristics of peripheral blood, immune phenotypes, fusion genes and cytogenetics of patients with t(8;21) acute myeloid leukemia(AML) through the retrospective analysis of 586 patients with t(8;21) AML from 15 blood disease research centers in Northern area of China.
METHODSThe factors affecting prognosis of patients with t(8;21) AML were investigated by using univariate and multivariate COX regression.
RESULTSThe immune type of t(8;21) AML patients was mainly with HLA-DR, CD117, CD34, MPO, CD38, CD13and CD33(>95%), part of them with CD19and CD56; the most common accompanied mutation of t(8;21) AML patients was C-KIT mutation (37.8%); in addition to t(8;21) ectopic, the most common chromosomal abnormality was sex chromosome deletions (38.9%). The univariate analysis revealed a significant survival superiority of OS and PFS in t(8;21) AML patients of WBC≤3.5×10/L without C-KIT mutation, the newly diagnosed ones achieved HSCT(P<0.05), only survival superiority on OS in t(8;21) AML patients with extramedullary infiltration and CD19 positive; the results of multivariate analysis showed a significant survival superiority on OS and PFS in t(8;21) AML patients with WBC≤3.5×10/L(P<0.05).
CONCLUSIONThe clinical features of t(8;21) AML patients in China are similar to those in other countries, WBC≤3.5×10/L is a good prognostic factor while the C-KIT mutation is a poor one in t(8;21) AML patients.